Clinical Trial

Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer

Study acronym: CHIMOVIP
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 11, 2021 (before its estimated October 2021 completion). Its status may not reflect the trial's current state.
Summary
CHIMOVIP is a study to determine the best therapeutic strategy in patient with ovarian advanced cancer.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2017-01-16; most recent amendment 2021-02-10.
Trial Details
NCT Number NCT03025477
Lead Sponsor Groupe Hospitalier Diaconesses Croix Saint-Simon
Collaborators: GERCOR - Multidisciplinary Oncology Cooperative Group
Conditions Ovarian Cancer, Epithelial
Enrollment 84 participants
Start Date 2016-10
Primary Completion 2021-10 (estimated)
Study Completion 2032-10 (estimated)
Updated on ClinicalTrials.gov 2021-02-11